Literature DB >> 9690965

Implications of brain imaging for the management of schizophrenia.

S Nyberg1, U Nilsson, Y Okubo, C Halldin, L Farde.   

Abstract

Positron emission tomography (PET) can be used to explore relationships between central neuroreceptor occupancy, psychotropic drug blood levels and clinical effects. Treatment with conventional neuroleptics induces high (70-90%) dopamine (D2)-receptor occupancy. The risk of extrapyramidal side effects increases at D2-receptor occupancies above 80%. Standard doses of clozapine induced a low (20-67%) D2-receptor occupancy, but very high (85-90%) 5-hydroxytryptamine (5-HT2A)-receptor occupancy. The novel antipsychotics risperidone and olanzapine induced high occupancy of both D2 and 5-HT2A receptors at suggested standard doses. The occurrence of extrapyramidal side effects in some patients in the higher dose ranges does not support the view that 5-HT2A-receptor occupancy completely prevents the development of extrapyramidal side effects. These results emphasize the need for further exploration of the low dose ranges of risperidone and olanzapine. A preliminary analysis of an ongoing PET study showed that a schizophrenic patient treated with sertindole at 20 mg/day had a D2-receptor occupancy of below 70%. Further studies are needed to show whether sertindole is the first new antipsychotic that induces low occupancy in the clinical dose range, suggesting a mechanism of action distinct from that of classical neuroleptics and analogous to that of clozapine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690965     DOI: 10.1097/00004850-199803003-00003

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  8 in total

Review 1.  Functional brain mapping of psychopathology.

Authors:  G D Honey; P C Fletcher; E T Bullmore
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

2.  Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.

Authors:  M Reimold; C Solbach; S Noda; J-E Schaefer; M Bartels; M Beneke; H-J Machulla; R Bares; T Glaser; H Wormstall
Journal:  Psychopharmacology (Berl)       Date:  2006-11-17       Impact factor: 4.530

Review 3.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

4.  [123I]Iodobenzamide binding to the rat dopamine D2 receptor in competition with haloperidol and endogenous dopamine--an in vivo imaging study with a dedicated small animal SPECT.

Authors:  Susanne Nikolaus; Rolf Larisch; Andreas Wirrwar; Marlyse Jamdjeu-Nouné; Christina Antke; Markus Beu; Nils Schramm; Hans-Wilhelm Müller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-08       Impact factor: 9.236

Review 5.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).

Authors:  Y Hodé; M Reimold; A Demazières; G Reischl; F Bayle; P Nuss; A Hameg; M Dib; J P Macher
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

7.  Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.

Authors:  W G Frankle; R Gil; E Hackett; O Mawlawi; Y Zea-Ponce; Z Zhu; L D Kochan; C Cangiano; M Slifstein; J M Gorman; M Laruelle; A Abi-Dargham
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

8.  Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors.

Authors:  Pablo Vázquez-Borsetti; Roser Cortés; Francesc Artigas
Journal:  Cereb Cortex       Date:  2008-11-21       Impact factor: 5.357

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.